These results indicate that androstano-arylpyrimidine 17-acetates are capable of inhibiting ABC transporter activity in Colo 320 adenocarcinoma cells, but they also suggest that the efflux transporter inhibiting capacity of this compound group is manifested in breast- and colon-derived multidrug-resistant cancer cells. The gene discussed is ABCG2; the disease is cancer.